Ovarian cancer remains one of the deadliest gynecologic cancers, largely because most cases are found after the disease has already spread. But the landscape is shifting in meaningful ways. Artificial intelligence is outperforming expert ultrasound examiners in spotting tumors. PARP inhibitors have become a standard part of treatment for many patients, and researchers are now tackling the thorny problem of resistance to those drugs. Newer targeted therapies, surgical techniques, prevention strategies, and early-detection tools are all moving through the pipeline. Here is where things stand across the most active areas of ovarian cancer research.
AI-Powered Imaging and Liquid Biopsies for Earlier Detection
The biggest unmet need in ovarian cancer is catching it early. No reliable screening test exists for the general population, and the blood marker CA125, while useful, misses too many early-stage cases. Two areas of research are gaining ground: artificial intelligence applied to imaging, and liquid biopsies that analyze tumor fragments circulating in the blood.
A large international study validated deep-learning models on more than 17,000 ultrasound images from patients across 20 centers in eight countries. The AI significantly outperformed both expert and non-expert examiners on every diagnostic metric tested. In a simulated triage scenario, AI-driven support cut referrals to specialist examiners by about 63 percent while still exceeding the diagnostic accuracy of current practice.1PubMed Central. International multicenter validation of AI-driven ultrasound detection of ovarian cancer That finding matters because access to expert ultrasound examiners is limited in many parts of the world, and an AI tool that fills that gap could change who gets diagnosed early.
On the liquid biopsy front, circulating tumor DNA (ctDNA) is being explored as a way to detect ovarian cancer from a blood draw. A systematic review found that ctDNA-based tests showed sensitivity ranging from roughly 41 to 95 percent and specificity from 56 to 100 percent, with some approaches outperforming CA125, especially for early-stage disease.2PubMed. Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review Those ranges are wide, which signals that the field hasn’t settled on the best method yet. But the direction is encouraging, and researchers are also testing multi-biomarker panels that combine several blood-based signals. Individual biomarkers tend to show only moderate accuracy on their own, but combined panels have achieved high accuracy in research settings.3PubMed Central. Breast and ovarian cancers: toward a multi-cancer early detection test Liquid biopsies are not yet standard clinical tools for ovarian cancer diagnosis, but they are increasingly seen as a promising route toward earlier detection and better treatment monitoring.4PubMed Central. Emerging Applications of Liquid Biopsies in Ovarian Cancer
PARP Inhibitors and What Happens When They Stop Working
PARP inhibitors have been one of the most significant advances in ovarian cancer treatment in recent years. These drugs work by blocking a DNA repair pathway that cancer cells rely on, and they are particularly effective when the tumor already has a weakness in a separate repair system called homologous recombination. Tumors with BRCA1 or BRCA2 mutations, or with a broader condition called homologous recombination deficiency (HRD), are the best candidates.
The clinical trial data behind these drugs is striking. In the SOLO-1 trial, patients with BRCA-mutated ovarian cancer who received olaparib as maintenance therapy had a median progression-free survival of roughly 50 months, compared to about 14 months with placebo. Niraparib, tested in the PRIMA trial in patients with HRD regardless of BRCA status, extended median progression-free survival to about 22 months versus 10 months with placebo. When olaparib was combined with bevacizumab in patients with HRD, the median progression-free survival stretched to about 37 months.5PubMed Central. Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer These numbers represent a real shift in how long patients can live without their cancer progressing.
Real-world data backs up the trial results, at least for the right patients. A study examining outcomes outside of clinical trials found that patients whose tumors tested positive for an HRD signature and received PARP inhibitor maintenance had significantly better progression-free survival. But patients whose tumors lacked that signature saw no meaningful benefit from the same drugs.6Clinical Cancer Research. Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice This underscores why molecular testing matters so much in guiding who should receive these treatments.
An important quality-of-life question hangs over long-term maintenance therapy: does staying on the drug make patients feel worse even if it delays recurrence? Data from the SOLO2 trial found that olaparib maintenance did not significantly harm health-related quality of life compared to placebo, and patients experienced meaningful benefits in time without symptoms of disease or toxicity.7The Lancet Oncology. Health-related quality of life and patient-centred outcomes with olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov-21)
The harder question is what to do when PARP inhibitors stop working. Tumors eventually develop resistance through several mechanisms, including restoring the very DNA repair pathways that the drugs were designed to exploit.8PubMed. PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy Multiple resistance mechanisms can be present simultaneously in the same patient, and they can evolve over time, making it a moving target.9International Journal of Gynecological Cancer. Overcoming PARP inhibitor resistance in ovarian cancer Researchers are now testing drugs that target different points of vulnerability, including ATR inhibitors, WEE1 inhibitors, and agents that block a backup DNA repair enzyme called POLQ. Early results with WEE1 and PLK1 inhibitors have shown they can induce DNA damage and cell death even in tumors that are proficient at homologous recombination, which is the group that PARP inhibitors help the least.10PubMed Central. PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer These drugs targeting DNA replication stress are still in early trials, but they represent one of the most watched areas in ovarian cancer research.11PubMed Central. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
Antibody-Drug Conjugates and Other Emerging Targeted Therapies
Antibody-drug conjugates, or ADCs, are a class of treatment designed to deliver chemotherapy directly to cancer cells while sparing healthy tissue. They work by linking a potent drug to an antibody that recognizes a specific protein on the surface of tumor cells. Several ADCs are now being tested in ovarian cancer, and at least one has reached the clinic.
Mirvetuximab soravtansine targets a protein called folate receptor alpha, which is present on the surface of most epithelial ovarian cancers. In a phase I expansion study of patients with platinum-resistant disease, the drug produced confirmed responses in about a quarter of patients, with higher response rates in those who had received fewer prior treatment lines.12PubMed Central. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer It has since received FDA accelerated approval for certain patients with platinum-resistant disease. More recently, combining mirvetuximab soravtansine with the checkpoint inhibitor pembrolizumab showed a response rate of about 31 percent in heavily pretreated patients, with a median duration of response of 8 months. Pneumonitis (lung inflammation) was a notable side effect, occurring in a quarter of participants, though severe cases were uncommon.13PubMed. Safety and efficacy of mirvetuximab soravtansine in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
Other ADC targets under investigation include NaPi2b, a phosphate transport protein found on many ovarian and lung cancers. A phase I expansion study reported clinical activity in high-grade serous ovarian cancer patients without preselecting for NaPi2b expression.14Journal of Clinical Oncology. Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC) Preclinical work is also exploring ADCs directed at additional targets including EGFR, Her2, Trop2, and tissue factor, all of which are commonly expressed on ovarian cancer cells.15PubMed Central. SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor Receptor 2, Trophoblast Cell-Surface Antigen 2, and Tissue Factor for Ovarian Cancer Treatment ADCs are increasingly seen as an important weapon for platinum-resistant disease, which has historically had limited treatment options.
Bevacizumab and the Tumor Microenvironment
Bevacizumab, a drug that blocks the growth of new blood vessels that tumors need to thrive, has been a part of ovarian cancer treatment for years. What’s evolving is the understanding of why it works and how it might be combined more effectively with other drugs. Ovarian cancers often grow in a low-oxygen environment that drives the formation of new blood vessels and simultaneously creates conditions that help tumors evade the immune system. Blocking this process with bevacizumab does more than just starve the tumor of blood supply; it can also worsen DNA damage within cancer cells and influence how immune cells move through the tumor. That biological rationale has led researchers to test three-drug combinations of bevacizumab, PARP inhibitors, and immune checkpoint inhibitors.16PubMed Central. Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers These combinations are being studied in several ongoing trials, and identifying biomarkers that predict which patients will benefit most from bevacizumab remains an active area of work.
Surgical Advances: Heated Chemotherapy and Fluorescence Guidance
Surgery to remove as much visible tumor as possible has long been the backbone of ovarian cancer treatment. Two innovations are making those operations more effective.
The first is HIPEC, or hyperthermic intraperitoneal chemotherapy, where heated chemotherapy is bathed directly inside the abdomen at the end of cytoreductive surgery. The Dutch OVHIPEC-1 trial reported that adding HIPEC to interval surgery extended median overall survival from about 33 months to about 45 months in patients with stage III epithelial ovarian cancer.17PubMed. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Ten-year follow-up data confirmed a lasting survival advantage.18The Lancet Oncology. 10-year survival results of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in ovarian cancer (OVHIPEC-1) A meta-analysis pooling additional data also found that HIPEC significantly improved progression-free survival in patients with newly diagnosed advanced disease who had received upfront chemotherapy.19PubMed Central. Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: a Meta-analysis HIPEC is not universally adopted yet, and confirmatory trials are ongoing in other countries, but the evidence base has grown substantially.
The second surgical innovation is fluorescence-guided surgery, where a targeted dye lights up cancer deposits that the surgeon’s eyes alone might miss. In a first-in-human study, a fluorescent agent that targets folate receptor alpha allowed surgeons to identify tumor implants that would have been invisible under standard white light, improving the completeness of tumor removal.20Nature Medicine. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results Other research has explored CD24-targeted fluorescence, which in preclinical models improved tumor detection by roughly 47 percent compared to standard surgery and reduced the amount of tumor left behind after the procedure.21EBioMedicine. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma Because leaving behind even tiny amounts of residual tumor is linked to worse outcomes, any technology that helps surgeons see more has real potential to improve survival.
Immunotherapy in Ovarian Cancer
Immunotherapy has transformed treatment for cancers like melanoma and lung cancer, but ovarian cancer has been a harder nut to crack. Checkpoint inhibitors used alone have generally shown disappointing results in ovarian cancer. The field is now focused on combinations and more creative approaches.
One strategy is combining immunotherapy with existing treatments. Research suggests that pairing checkpoint inhibitors with chemotherapy, anti-angiogenic drugs, or PARP inhibitors can boost immune responses that the tumor otherwise suppresses.22PubMed Central. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant The mirvetuximab-pembrolizumab combination mentioned earlier is one example of this approach being put into practice.
Cancer vaccines represent another avenue. In a pilot clinical trial, a personalized vaccine made from a patient’s own dendritic cells pulsed with treated tumor material was given to patients with recurrent ovarian cancer. The vaccine stimulated immune responses against the patient’s own tumor, including against mutated proteins unique to that tumor. Those immune responses were associated with significantly longer survival, and the vaccine was administered without serious adverse events across nearly 400 doses.23PubMed. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer A separate small trial of a dendritic cell vaccine in patients in remission reported that six of nine patients who completed all vaccine doses remained disease-free at 36 months, with three-year overall survival of 90 percent.24PubMed Central. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission These are small studies, but the results are encouraging enough to justify larger trials.
CAR-T cell therapy, which has been transformative for certain blood cancers, is also being explored for ovarian cancer. Researchers are engineering patients’ own immune cells to recognize targets commonly found on ovarian tumors, including MUC16, mesothelin, and folate receptor alpha.25PubMed. A new approach to the treatment of ovarian cancer: The application of CAR-T cell therapy One clinical trial is testing CAR-T cells that target MUC16 and are further engineered to secrete an immune-boosting molecule called IL-12, which helps the cells persist longer and reshape the hostile tumor environment.26PubMed Central. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer Solid tumors pose unique challenges for CAR-T therapy that blood cancers do not, including getting the engineered cells to physically reach the tumor and function in its immunosuppressive environment. This work is still early-stage, but it reflects a real investment in making cellular therapy work for ovarian cancer.
Low-Grade Serous Ovarian Cancer as a Separate Disease
Not all ovarian cancers are the same, and one of the more significant recent shifts has been recognizing low-grade serous ovarian cancer (LGSOC) as a genuinely distinct disease from its high-grade counterpart. High-grade serous ovarian cancer, the most common type, is driven by TP53 mutations and genomic instability. Low-grade serous tumors, by contrast, are characterized by mutations in the MAPK signaling pathway, particularly KRAS and BRAF, and they grow more slowly.27Cancer Treatment Reviews. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy Patients with low-grade tumors tend to survive longer overall, but their cancers respond poorly to standard platinum-based chemotherapy, which is a frustrating paradox.
These molecular differences are now shaping treatment. Because many low-grade tumors are estrogen-receptor positive, hormonal therapy is widely used for maintenance. More targeted options are in clinical trials, including MEK inhibitors that directly attack the overactive MAPK pathway, sometimes combined with hormonal therapy.28Cancer Treatment Reviews. Low-grade serous ovarian cancer: Recent advances in molecular understanding and emerging therapies Researchers have also identified CDKN2A mutations in a subset of low-grade tumors, which has opened the door to testing CDK4/6 inhibitors, drugs already approved for breast cancer.29International Journal of Gynecological Cancer. Molecular changes driving low-grade serous ovarian cancer and implications for treatment The key takeaway for patients is that treatment for low-grade serous ovarian cancer should not simply mirror what is given for the high-grade type.
Genetic Testing and Why It Matters Beyond Heredity
Roughly one in four to one in five patients with epithelial ovarian cancer carry inherited mutations in genes involved in DNA repair, most commonly BRCA1 and BRCA2. Additional genes in the homologous recombination pathway have since been identified, and mutations in mismatch repair genes account for another 10 to 15 percent of hereditary cases.30PubMed Central. Current practices on genetic testing in ovarian cancer These findings matter for two reasons: they inform whether family members should be screened, and they determine which treatments are most likely to work, especially PARP inhibitors.
Multigene panel testing, which checks many cancer-related genes simultaneously rather than just BRCA1 and BRCA2, has revealed clinically relevant mutations in about 4.5 percent of patients who tested negative for BRCA alone.31PubMed. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients Guidelines now broadly recommend genetic testing for all patients diagnosed with epithelial ovarian cancer, regardless of family history or age at diagnosis, because the results directly influence treatment decisions.
Patient-Derived Organoids for Personalized Drug Testing
A more recent development is the use of patient-derived organoids, which are miniature three-dimensional tumor models grown in the lab from a patient’s own cancer cells. The idea is to test drugs on the organoid before giving them to the patient, essentially running a preview of which treatments will work.
Studies have shown that these organoids faithfully capture the genetic profiles of the original tumors and can reproduce their drug-sensitivity patterns. In one study, an organoid derived from a tumor with a BRCA1 mutation showed significantly higher sensitivity to olaparib compared to organoids from tumors without that mutation, and organoid responses to platinum drugs matched the patients’ actual clinical courses.32Scientific Reports. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing Drug testing across a panel of ten ovarian cancer organoids revealed substantial differences in sensitivity between individual patients, even when tumors were the same histological type.33PubMed Central. In vitro drug testing using patient-derived ovarian cancer organoids Another preliminary study confirmed that organoids could replicate key mutations and copy-number changes from the original tumors, positioning them as potential tools for guiding personalized treatment.34PubMed Central. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness This technology is not yet routine in clinical care, but it represents a plausible path toward choosing therapies based on each patient’s individual tumor biology rather than population-level statistics.
Opportunistic Salpingectomy for Prevention
Research over the past two decades has established that many high-grade serous ovarian cancers originate not in the ovary itself but in the far end of the fallopian tube. That realization has led to a practical prevention strategy: removing the fallopian tubes during any abdominal surgery where a woman was already under anesthesia, a practice called opportunistic salpingectomy. The ovaries are left in place, preserving hormone function.
This practice is already being adopted in several countries.35PubMed Central. Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany Recommendations now include performing the procedure at the time of hysterectomy or in place of standard tubal ligation in women at average risk.36PubMed Central. Opportunistic salpingectomy for ovarian cancer prevention A cost-effectiveness modeling study estimated that if opportunistic salpingectomy were performed at the time of hysterectomy and sterilization in Germany, it could prevent roughly 400 ovarian cancer cases per year and reduce ovarian cancer deaths by about 5.7 percent. Expanding the approach to any eligible abdominal surgery could prevent over 1,000 cases annually and cut deaths by about 16 percent.37PLOS Medicine. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study For a cancer that lacks an effective screening test, removing the tissue of origin during unrelated surgery is a pragmatic and increasingly accepted prevention measure.
Who Gets Access to These Advances
None of these medical advances matter equally if access is uneven. A study of Medicare patients with advanced ovarian cancer found that non-Hispanic Black patients were significantly less likely to receive targeted therapies compared to non-Hispanic White patients, even after accounting for other factors.38PubMed Central. Racial and Sociodemographic Disparities in the Use of Targeted Therapies in Advanced Ovarian Cancer Patients with Medicare Separate research has documented that patients of non-European ancestry and those with public insurance receive fewer referrals to genetic testing after an ovarian cancer diagnosis. Because genetic testing results directly influence whether a patient is offered PARP inhibitors, missed referrals translate into missed treatment opportunities. These disparities mean that the people who might benefit most from precision medicine are sometimes the least likely to receive it, and closing that gap is as urgent as any laboratory breakthrough.